Literature DB >> 1903343

Intensive liver care and management of acute hepatic failure.

R Williams1, A E Gimson.   

Abstract

In describing acute liver failure, the term fulminant hepatic failure (FHF) is used to denote patients with the most rapid progression, normally defined as the onset of encephalopathy within eight weeks of the onset of symptoms. For patients with a slower onset of encephalopathy, ranging from eight weeks to six months after the onset of symptoms, late-onset hepatic failure is the term used to reflect the overlap in clinical features with some patients with FHF. The importance of accurately determining the type of acute liver failure results from increasing evidence of an inverse relationship between the tempo of disease progression and the chances of recovery. Prognosis is also dependent on the underlying etiology. Principles of management are as follows: (1) an accurate recognition of the tempo of the hepatic failure--fulminant, late onset, acute on chronic--and the establishment of a likely etiology; (2) early detection and treatment of complications, particularly metabolic acidosis (early), renal failure, cerebral edema, and infection (late); (3) optimization of conditions for regeneration by maintenance of a near normal metabolic milieu (with removal of toxins by various methods of artificial liver support if necessary); and (4) early consideration of an orthotopic liver transplant for those patients in the poor prognosis group. Variations in the natural history and clinical features of acute liver failure (ALF) have led to a number of different classifications and subgroupings. Knowledge of these is important in relation to the assessment of prognosis and is even more important now that transplantation is a therapeutic option.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1903343     DOI: 10.1007/bf01311243

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  25 in total

1.  H2-receptor antagonist in the prevention of acute upper gastrointestinal hemorrhage in fulminant hepatic failure: a controlled trial.

Authors:  B R MacDougall; R Williams
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

2.  Dialysis in the treatment of renal failure in patients with liver disease.

Authors:  S P Wilkinson; M J Weston; V Parsons; R Williams
Journal:  Clin Nephrol       Date:  1977-07       Impact factor: 0.975

Review 3.  Coagulopathy of fulminant hepatic failure.

Authors:  J G O'Grady; P G Langley; L M Isola; L M Aledort; R Williams
Journal:  Semin Liver Dis       Date:  1986-05       Impact factor: 6.115

Review 4.  Fulminant and subfulminant liver failure: definitions and causes.

Authors:  J Bernuau; B Rueff; J P Benhamou
Journal:  Semin Liver Dis       Date:  1986-05       Impact factor: 6.115

5.  Acute hepatic failure--in special relation to treatment.

Authors:  Y Takahashi
Journal:  Jpn J Med       Date:  1983-04

6.  Etiology of fulminant viral hepatitis in Greece.

Authors:  G Papaevangelou; N Tassopoulos; A Roumeliotou-Karayannis; C Richardson
Journal:  Hepatology       Date:  1984 May-Jun       Impact factor: 17.425

7.  Emergency liver transplantation for fulminant hepatitis.

Authors:  H Bismuth; D Samuel; J Gugenheim; D Castaing; J Bernuau; B Rueff; J P Benhamou
Journal:  Ann Intern Med       Date:  1987-09       Impact factor: 25.391

8.  Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure.

Authors:  J G O'Grady; A E Gimson; C J O'Brien; A Pucknell; R D Hughes; R Williams
Journal:  Gastroenterology       Date:  1988-05       Impact factor: 22.682

9.  Serological markers in fulminant hepatitis B.

Authors:  A E Gimson; R S Tedder; Y S White; A L Eddleston; R Williams
Journal:  Gut       Date:  1983-07       Impact factor: 23.059

10.  Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure.

Authors:  J Canalese; A E Gimson; C Davis; P J Mellon; M Davis; R Williams
Journal:  Gut       Date:  1982-07       Impact factor: 23.059

View more
  7 in total

Review 1.  Treatment of acute liver failure.

Authors:  K H Boeker
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

2.  The effect of molecular adsorbent recirculating system on pathophysiological parameters in patients with acute liver failure.

Authors:  Wai Kwan Lai; Geoff Haydon; David Mutimer; Nick Murphy
Journal:  Intensive Care Med       Date:  2005-09-10       Impact factor: 17.440

Review 3.  Extracorporeal liver support.

Authors:  Jan Stange
Journal:  Organogenesis       Date:  2011-01-01       Impact factor: 2.500

Review 4.  Hepatic disorders. Features and appropriate management.

Authors:  M A Aldersley; J G O'Grady
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

5.  Orthotopic liver transplantation in fulminant and subfulminant hepatitis. The Paul Brousse experience.

Authors:  H Bismuth; D Samuel; D Castaing; R Adam; F Saliba; M Johann; D Azoulay; B Ducot; L Chiche
Journal:  Ann Surg       Date:  1995-08       Impact factor: 12.969

6.  Histological changes during extracorporeal perfusions of the porcine liver: implications for temporary support during acute liver failures.

Authors:  Gianpiero Gravante; Seok Ling Ong; Angus McGregor; Roberto Sorge; Matthew S Metcalfe; David M Lloyd; Ashley R Dennison
Journal:  J Artif Organs       Date:  2012-11-27       Impact factor: 1.731

7.  Exogenous adenosine 5'-triphosphate does not improve survival in rats with acute liver failure.

Authors:  Erin P Becker; DongFeng Sun; Gerald Y Minuk
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.